Pfizer Inc. $PFE Shares Sold by AGF Management Ltd.

AGF Management Ltd. lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 847,898 shares of the biopharmaceutical company’s stock after selling 49,682 shares during the quarter. AGF Management Ltd.’s holdings in Pfizer were worth $21,604,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Pfizer during the second quarter worth $2,270,157,000. Vanguard Group Inc. raised its holdings in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Pfizer by 43.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after acquiring an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Pfizer by 75.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after acquiring an additional 3,722,531 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.9%

Pfizer stock opened at $26.68 on Tuesday. The stock has a market cap of $151.67 billion, a PE ratio of 15.51 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock’s fifty day moving average is $25.54 and its two-hundred day moving average is $25.05. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $27, citing a shifting focus on obesity data that could re-rate Pfizer if pipeline results improve. Cantor Fitzgerald Raises PT to $27
• Positive Sentiment: UK industry self-regulator found Sanofi breached rules with unsubstantiated claims about its RSV therapy versus Pfizer’s vaccine — a reputational win that supports Pfizer’s vaccine positioning. Sanofi Breach Over RSV Claims
• Positive Sentiment: Management is reshaping the portfolio toward obesity, vaccines and pricing changes; investors see this as a potential multi-year growth pivot and yield support (Pfizer is highlighted for income investors). Pfizer Reshapes Portfolio With Obesity Bet
• Neutral Sentiment: Q4 earnings are due Feb. 3 before the open; previews focus attention on pipeline commentary (especially obesity/GLP-1 positioning) and guidance — the release, not yet reflected in results, is the main near-term catalyst. Is Pfizer a Good Stock to Buy before Earnings?
• Negative Sentiment: Several outlets and analyst models expect lower Q4 earnings and some firms have trimmed forecasts ahead of the call — downside surprise to EPS or guidance could pressure the stock. Pfizer Likely To Report Lower Q4 Earnings
• Negative Sentiment: Ongoing structural headwinds — patent expiries on blockbusters, intense GLP?1 competition and pricing pressure — remain material risks that could limit upside absent strong pipeline news. 3 Headwinds Facing Pfizer in 2026

Analyst Ratings Changes

Several analysts have recently issued reports on PFE shares. Bank of America reduced their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. HSBC reissued a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Cantor Fitzgerald lifted their target price on Pfizer from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.